Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus

• Published in: Scientific reports Vol. 13; no. 1; p. 21327
• Main Authors: Kuo, Hsiao-Huai, Lai, Yau-Huei, Lin, Po-Lin, Chen, Hsin-Hao, Hung, Chung-Lieh, Liu, Lawrence Yu-Min, Yeh, Chih-Kuang
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 03.12.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 692/163; 692/4019; Antidiabetics; Blood pressure; Body weight; Canagliflozin - pharmacology; Canagliflozin - therapeutic use; Cardiovascular diseases; Clinical trials; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2; Echocardiography; Female; Health risks; Heart; Heart Atria; Hematocrit; Hemodynamics; Humanities and Social Sciences; Humans; Male; multidisciplinary; Observational studies; Patients; Science; Science (multidisciplinary); Sodium-glucose cotransporter; Stroke Volume; Ventricle; Ventricular Function, Left; Ventricular Remodeling
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-48716-y

Sodium-glucose cotransporter type 2 (SGLT2) inhibitors have demonstrated to reduce cardiovascular risk in patients with type 2 diabetes mellitus (T2DM) in large trials independent of glycemic control. The mechanisms of this cardioprotective property remain uncertain. Evidence suggests positive hemodynamic changes and favorable cardiac remodeling contributing to the clinical outcomes but results were conflicting. We aim to investigate the potential impact on hemodynamic parameters, cardiac structure and functions. This prospective observational study included T2DM patients receiving canagliflozin 100 mg per day in addition to their antidiabetic treatment. We analyzed hemodynamic parameters assessed by echocardiographic measurements and impedance cardiography (ICG) to evaluate systolic and diastolic functions from baseline to 24 weeks after treatment. A total of 47 patients (25 males and 22 females) averaging 64.6 ± 10.9 years had a significant reduction in HbA1c, body weight, and systolic blood pressure. Hematocrit increased significantly, while NT-proBNP remained unchanged. E/e′, left atrium (LA) volume, and LA stiffness were reduced, while left ventricle (LV) global longitudinal strain (GLS) and LA strain rates increased at 24 weeks by conventional and speckle tracking echocardiography. LV mass and ejection fraction showed no differences. ICG suggested significant improvement in hemodynamic parameters with increased stroke volume index and cardiac output index and decreased systemic vascular resistance index at 12 and 24 weeks. Canagliflozin improved hemodynamic parameters and had a favorable impact on LA and LV reverse remodeling. These changes may explain the beneficial effect on cardiovascular outcomes in large clinical trials.